Your session is about to expire
← Back to Search
Tumor Necrosis Factor Inhibitor
Enbrel for Uveitis in Juvenile Arthritis
Phase 3
Waitlist Available
Research Sponsored by National Eye Institute (NEI)
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Must have active anterior uveitis defined as the presence of inflammatory cells (Grade 1+ or higher) in the anterior chamber of at least one eye or the current use of topical corticosteroids to control exacerbation of disease at a frequency of TID or higher
Be up to date on all recommended childhood immunizations
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
Study Summary
This trial will study the use of Enbrel to treat uveitis in patients with juvenile rheumatoid arthritis.
Who is the study for?
Children and teenagers aged 2 to 18 with juvenile rheumatoid arthritis and active eye inflammation (uveitis) can join. They must be able to follow the study plan, have had a stable arthritis treatment for at least 8 weeks, and meet specific criteria for their condition. Pregnant or breastfeeding individuals, those with certain medication use or serious infections, or who cannot undergo necessary eye exams are excluded.Check my eligibility
What is being tested?
The trial is testing Enbrel (TNFR:Fc), a drug designed to treat uveitis in young patients with juvenile rheumatoid arthritis. The effectiveness of this drug will be measured by its ability to reduce eye inflammation without causing significant side effects.See study design
What are the potential side effects?
Enbrel may cause reactions at the injection site, increase the risk of infections due to immune system suppression, cause headaches and nausea. It's important that participants are monitored closely for any adverse effects throughout the trial.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I have active inflammation in the front part of my eye or I'm using eye drops frequently to control it.
Select...
I am up to date with all my childhood vaccinations.
Select...
I am between 2 and 18 years old.
Select...
I have been diagnosed with juvenile rheumatoid arthritis.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Find a Location
Who is running the clinical trial?
National Eye Institute (NEI)Lead Sponsor
546 Previous Clinical Trials
1,401,994 Total Patients Enrolled
47 Trials studying Uveitis
18,174 Patients Enrolled for Uveitis
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I haven't had eye injections or new experimental treatments recently.I am not pregnant or breastfeeding.I do not have any serious infections or a history of them.I do not have spine or tendon attachment inflammation.I am not on DMARDs, except possibly low-dose prednisone or methotrexate.I don't need new or more anti-inflammatory medication for eye or joint inflammation.I have been on my arthritis treatment for at least 8 weeks.I have active inflammation in the front part of my eye or I'm using eye drops frequently to control it.I am up to date with all my childhood vaccinations.I am between 2 and 18 years old.I haven't used Latanoprost in the last two weeks and don't expect to need it during the study.I have been diagnosed with juvenile rheumatoid arthritis.
Research Study Groups:
This trial has the following groups:Awards:
This trial has 2 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Could you please outline the risks and side-effects associated with this medication?
"This is a Phase 3 clinical trial, so there is some existing data to support the efficacy of the treatment and multiple rounds of safety data. Therefore, our team has rated the safety as a 3."
Answered by AI
Does this test group include geriatric patients?
"As this is a paediatric trial, only patients aged 2 to 18 can be included. Out of the 427 total clinical trials currently underway, 68 are for minors and 359 are for elderly patients."
Answered by AI
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger